TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: Children with cerebral palsy (CP) undergo multiple painful procedures such as Botulinum toxin (BTX) injections that are administered several times a year. While clown care reduces preoperative anxiety, its effect on painful procedures has not been assessed. We hypothesized that medical clowning reduces pain and anxiety during BTX injections.


Options:
A: Inclusion Criteria:

* ages 5-9 years,
* boys and girls

Exclusion Criteria:

* children with pervasive developmental disability
B: Inclusion Criteria:

* Children with CP for whom BTX treatment was indicated

Exclusion Criteria:

* Children with minimal communication skills (n =1)
* Autistic spectrum disorders (n =1)
* Severe anxiety requiring general anesthesia (n =1)
C: Inclusion Criteria:

* Children attending the pediatric ED between the ages of 3 and 6 years - Undergoing an IV placement
* Conscious
* Have sufficient knowledge of the English language to understand and follow instructions and complete the age-appropriate pain assessment

Exclusion Criteria:

* Children with hearing impairments, developmental disabilities, or sensory impairment to pain (e.g., spina bifida)
* Children will be excluded at the discretion of the attending staff (e.g., child in critical condition; requires urgent IV placement; or has altered level of consciousness).
D: Inclusion Criteria:

* Children, ages 4-6 years, scheduled to receive the standard pre-kindergarten immunizations. This consists of two injections: the Dtap (diphtheria, tetanus, acellular pertussis) and IPV (injectable polio vaccine) or three injections: DTAP, IPV and MMR (measles, mumps, rubella);
* With or without prior exposure to ST at PMG;
* English speaking subject and parents

Exclusion Criteria:

* Acute concurrent illness;
* Invasive procedures such as cannulation, venipuncture or urinary VCG in the preceding 6 months;
* Hospitalization or ED visit, within the prior 6 months;
* Chronic medical conditions requiring repeated painful interventions;
* Inability to respond age appropriately with verbal and written answers to questions, to pain scale measures, or to questionnaires;
* Refusal to be videotaped.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: Children with cerebral palsy (CP) undergo multiple painful procedures such as Botulinum toxin (BTX) injections that are administered several times a year. While clown care reduces preoperative anxiety, its effect on painful procedures has not been assessed. We hypothesized that medical clowning reduces pain and anxiety during BTX injections.


Options:
A: Inclusion Criteria:

1. Healthy infants undergoing vaccination.

Exclusion Criteria:

1. preterm birth (\<37 weeks gestation)
2. prior hospitalization/surgery (other than postnatal care),
3. documented/ suspected sensitivity/allergy to amide anaesthetics/vaccines,
4. mother plans to breastfeed or to use topical anesthetics or sugar water during injection.
B: Inclusion Criteria:

* Children with CP for whom BTX treatment was indicated

Exclusion Criteria:

* Children with minimal communication skills (n =1)
* Autistic spectrum disorders (n =1)
* Severe anxiety requiring general anesthesia (n =1)
C: Inclusion Criteria:

* premature infants with gestational age less than 36 weeks,
* clinically stable, showing behavioral abnormalities such as intolerance to the touch, excessive crying, showing signs of pain in accordance with the scale
* difficulty of NFCS leave the stage of crying and agitation for a period of deep sleep during a period of not less than 60 minutes.

Exclusion Criteria:

* premature medically unstable because of the difficulty of monitoring in liquid medium, with a change in temperature on mechanical ventilation who had an infectious process due to the exacerbation of it in hot water, and syndromic children with congenital facial deformities that impede the use of scale NFCS for evaluation.
D: Inclusion Criteria:

* mothers rooming in with infants on postnatal ward

Exclusion Criteria:

* mothers with significant psychiatric conditions
* mothers unable to communicate in English
* mothers sharing room whereby another mother already participated

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Peritoneal Lavage With Clindamycin-gentamicin Solution on Infection in Elective Surgery
Brief Summary: Intrabdominal antibiotic irrigation will reduce wound and intrabdominal infection.


Options:
A: Inclusion Criteria:

* diagnosis of colorectal neoplasms and plans to undergo an elective surgery with curative aims.

Exclusion Criteria:

* preoperative diagnosis of chronic renal failure, because of the risk of nephrotoxicity associated with intraperitoneal gentamicin absorption
* an anastomotic leak in the postoperative course
B: Inclusion Criteria:

* diagnosis of mammary neoplasms and plans to undergo an elective ALND of Berg´s levels I and II due to axillary metastasis determined preoperatively by core biopsy or evidence of metastasis in the SLNB in the intraoperative or in the differed analysis.

Exclusion Criteria:

* chronic renal failure due to possible toxicity of gentamicin
* patients undergoing a modified radical mastectomy.
C: Inclusion Criteria:

* skeletally mature
* sustained an open fracture of the appendicular skeleton (type I to IIIb).

Exclusion Criteria:

* vascular deficit
* \[any\] allergy to detergents or castile soap
* previous wound infection or osteomyelitis
* previous fracture with retained hardware in the injured extremity
* operative management more than 24 hours after injury
* use of immunosuppressive medication within six months
* immunological deficiency or disease conditions
* fractures of the hands (distal to the carpus) or toes
D: Inclusion Criteria:

* Children under 18 years
* Non-perforated appendicitis

Exclusion Criteria:

* Perforated appendicitis as identified as a hole in the appendix for fecalith in the abdomen

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients
Brief Summary: This randomized trial will evaluate whether varenicline directly observed therapy provided at a methadone clinic is more efficacious than self-administered varenicline for promoting smoking cessation and enhancing adherence.


Options:
A: Inclusion Criteria:

* Subjects must have smoked an average of at least 15 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

Exclusion Criteria:

* Subjects with clinically significant cardiovascular disease in the past 6 months.
B: Inclusion Criteria:

* Age 18 years or older
* English speaking
* Smoked at least 100 cigarettes/lifetime
* Smoke 5 or more cigarettes per day
* Interested in quitting smoking (preparation or contemplation stage of change)
* Enrolled in Einstein/Montefiore methadone program for 12 weeks or more
* Receiving methadone in clinic three, four, five or six times per week
* No more than 2 methadone clinic misses in prior 14 days
* Agree to use contraception for the duration of the trial (among women with reproductive potential)
* Willing to participate in all study components
* Able to provide informed consent

Exclusion Criteria:

* Serious or unstable HIV/AIDS, liver, cardiovascular, or pulmonary disease
* Psychiatric instability
* Women who are pregnant, breastfeeding, or contemplating pregnancy
* Creatinine clearance \<30 mL/min
C: Inclusion Criteria:

* Adult dental patient presenting for an exam visit whose most recent history reports the patient is a smoker. Patients had to agree to the phone survey.

Exclusion Criteria:

* Research opt out list
* Patients who discontinued the survey prior to completion(considered withdrawals)
D: Inclusion Criteria:

* Smoking 35 or more cigarettes per week or 5 or more cigarettes per day,
* Smoking for at least 2 years, with no period of abstinence longer than 3 months.

Exclusion Criteria:

* Using any smoking cessation drugs or nicotine replacement drugs in the last 3 months,
* Use of medication to treat depression or any psychiatric illness,
* Impaired renal function,
* Unstable medical condition,
* Pregnancy or breast feeding.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Probiotics Supplementation and Nutritional Benefit in Premature Infants
Brief Summary: The main objective is to assess the nutritional benefit of probiotics supplementation on premature infants growth. As secondary objectives, different parameters related to probiotics tolerance will be measured.


Options:
A: Inclusion criteria

* Gestational age between 26 weeks and 31 weeks
* Birth weight between 700 to 1600 g
* Eutrophic infants (weight between -2 to 2 DS, Usher curves)
* Admitted to one of the participating hospital unit within the 8 days following the birth, the birth date equals the 1st day of life.
* Still on parenteral feeding or infusion on the 5th day of birth

Non inclusion criteria

* Digestive disorders \> or equal to 1b on Bell stage
* Severe intra-ventricular haemorrhage (stage 3-4) before 5th day of life.
* Severe malformations or digestive malformations
* No antenatal corticosteroid therapy
* Severe medical or surgical disorder affecting the absorption, digesting and as a result the growth (Hirschsprung disease, lactose intolerance, cow milk protein allergy, mucoviscidosis).
* Parents geographical distance preventing the hospitalization follow-up in the hospital participating unit (geographical distance planned before the infant reaches 1500 g or 32 weeks of gestational age)

Exclusion criteria

* Enteral/Oral feeding termination during more than 72 hours due to severe digestive disorders (\> or equal to 2a on Bell stage )
* Serious digestive surgery
B: Inclusion Criteria:

* Admission to the NICU
* Written parental consent
* Birth weight \< 2000 grams
* Hemodynamically stable
* \< 48 hours of age

Exclusion Criteria:

* Evidence or suspicion of congenital intestinal obstruction or perforation
* Prenatal or postnatal diagnosis of gastroschisis, large omphalocele, or congenital diaphragmatic hernia
* Major congenital heart defects
* Anticipated transfer to a NICU not involved in the study
C: Inclusion Criteria:

1. newborns (\< 2 weeks of life)
2. 32 Weeks of Gestation,
3. weight \< 1500g,
4. Enteral nutrition begun,
5. Clinical stability,
6. Signed consent form from both parents.

Exclusion Criteria:

1. newborns (\>= 2 weeks of life),
2. weight \>= 1500g,
3. pathology avoiding the start of the enteral nutrition,
4. other pathologies of those due to premature and its complications,
5. No signed consent form.
D: Inclusion Criteria:

* Infants born less than 29 weeks gestation and \<1000 g birth weight admitted to the Neonatal Intensive Care Unit (NICU) at Foothills Medical Centre in Calgary.

Exclusion Criteria:

* Infants with major congenital anomalies, hypoxic-ischemic injury, NEC or bowel perforation before 72 hours of life.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Probiotics Supplementation and Nutritional Benefit in Premature Infants
Brief Summary: The main objective is to assess the nutritional benefit of probiotics supplementation on premature infants growth. As secondary objectives, different parameters related to probiotics tolerance will be measured.


Options:
A: Inclusion criteria

* Gestational age between 26 weeks and 31 weeks
* Birth weight between 700 to 1600 g
* Eutrophic infants (weight between -2 to 2 DS, Usher curves)
* Admitted to one of the participating hospital unit within the 8 days following the birth, the birth date equals the 1st day of life.
* Still on parenteral feeding or infusion on the 5th day of birth

Non inclusion criteria

* Digestive disorders \> or equal to 1b on Bell stage
* Severe intra-ventricular haemorrhage (stage 3-4) before 5th day of life.
* Severe malformations or digestive malformations
* No antenatal corticosteroid therapy
* Severe medical or surgical disorder affecting the absorption, digesting and as a result the growth (Hirschsprung disease, lactose intolerance, cow milk protein allergy, mucoviscidosis).
* Parents geographical distance preventing the hospitalization follow-up in the hospital participating unit (geographical distance planned before the infant reaches 1500 g or 32 weeks of gestational age)

Exclusion criteria

* Enteral/Oral feeding termination during more than 72 hours due to severe digestive disorders (\> or equal to 2a on Bell stage )
* Serious digestive surgery
B: Inclusion Criteria:

* Pregnant women from families with at least one family member having an allergic disease

Exclusion Criteria:

* Women presenting severe immunological or other chronic diseases (rheumatoid arthritis, diabetes, inflammatory bowel disease, thyroid diseases, malignancies etc.)
* Women who cannot be expected to comply with treatment
* Women currently participating or having participated in other clinical trial during the last 2 months prior to the beginning of the intervention.
C: Inclusion Criteria:

* VLBW infants admitted to NICU at the first 7 days of life

Exclusion Criteria:

* expected life lower than 7 days,
* babies who could not be fed (any metabolic disorders, gastrointestinal system surgical disorders etc.),
* severe asphyxia,
* severe congenital anomaly
D: Inclusion Criteria:

* Admission to the NICU
* Written parental consent
* Birth weight \< 2000 grams
* Hemodynamically stable
* \< 48 hours of age

Exclusion Criteria:

* Evidence or suspicion of congenital intestinal obstruction or perforation
* Prenatal or postnatal diagnosis of gastroschisis, large omphalocele, or congenital diaphragmatic hernia
* Major congenital heart defects
* Anticipated transfer to a NICU not involved in the study

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Randomized, Crossover, Multicenter Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Subjects With Type 2 Diabetes Mellitus
Brief Summary: The purpose of this study is to evaluate the effect of canagliflozin on post-meal glucose blood levels in patients with Type 2 Diabetes Mellitus.


Options:
A: Inclusion criteria:

* Male and female patients with type 2 diabetes and with glomerular filtration rate (GFR) \<30 ml/min, who are not on chronic dialysis.
* Insufficient glycemic control (hemoglobin A1c (HbA1c) between 7.0% and 10.0%)
* Age 18 or over and not older than 80 years

Exclusion criteria:

* Treatment with any other anti diabetic drug other than insulin and/or sulphonylurea within 3 months prior to informed consent
* Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months prior to informed consent
* Unstable or acute congestive heart failure
B: Inclusion Criteria:

* Patients with T2DM with inadequate glycemic control (based upon fasting glucose measurements \>=130 mg/dL and \<=250 mg/dL) on metformin monotherapy or on metformin in dual combination with other glucose lowering agents (sulphonylurea \[SU\] or a meglitinide or a dipeptidyl peptidase-4 \[DPP-4\] inhibitor) are eligible for enrollment in the study.

Exclusion Criteria:

* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
* history of a severe hypoglycemic episode within 6 months before screening
* Has repeated (ie, 2 or more over a 1-week period) fasting plasma glucose (FPG) and/or fasting self-monitored blood glucose (SMBG) measurements \>=250 mg/dL (13.88 mmol/L) during the pre-treatment phase, despite reinforcement of diet and exercise counseling
* History of or current illness considered to be clinically significant by the investigator
C: Inclusion Criteria:

* Has T2DM
* Has HbA1c between 6.5% (48 mmol/mol) and 8.0% (64 mmol/mol) on stable dose(s) of antihyperglycemic agent(s), including insulin
* Has pre-existing cardiovascular disease

Exclusion Criteria:

* Has a history of type 1 diabetes mellitus or ketoacidosis.
* Is not able to take sitagliptin
D: Inclusion Criteria:

Born 1930 or later, Type 1 diabetes appearing at age 30 or earlier and with insulin dependency within 1 year from diagnosis, no known abuse of alcohol or drugs, non-prolipherative retinopathy of any degree present, no previous photocoagulation, normal serum creatinine, unsatsifactory blood glucose control according to the physician in charge of the patients.

Exclusion Criteria:

Any history or ongoing ischemic foot ulcer,or peripheral artery disease,or osteoartropathy.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Evaluation of AlcoholEdu: A Randomized Multi-Campus Trial
Brief Summary: The study examined whether an online course for college freshmen (AlcoholEdu) had an effect on alcohol misuse and related problems, using a randomized controlled design with 30 universities.


Options:
A: Inclusion Criteria:

* Colleges without an online alcohol prevention course
* Able to implement AlcoholEdu course for all incoming freshmen
* Able to provide random student samples for data collection
* Able to obtain IRB approval for study

Exclusion Criteria:

* Already implementing alcohol prevention course for incoming freshmen
* Not able to implement online alcohol prevention course
* Not able to provide random student samples for data collection
* Not able to obtain IRB approval for study
B: Inclusion Criteria:

* adolescents (ages 14-18) presenting to the ED for a medical injury or illness (except exclusions as noted below)
* adolescents ability to provide informed assent/consent depending on age
* access to a parent or guardian to provide informed consent

Exclusion Criteria:

* adolescents who do not understand English
* prisoners
* adolescents classified by medical staff as "Level 1" trauma
* adolescents deemed unable to provide informed consent
* adolescents treated in the ED for suicide attempts
* adolescents triaged to the psychiatric ED
C: Inclusion Criteria:

* 18 years or older
* have home access to the Internet
* interested in receiving a computerized assessment of their drinking
* have a score of 8 or higher on the AUDIT.
D: Inclusion Criteria:

* age \>21 years
* frequent alcohol use
* willing to use a cell phone and breathalyzer for 28 days
* have a valid photo ID (driver's license, passport, state ID)
* are willing to sign an off-campus property transfer form and return study equipment in four weeks

Exclusion Criteria:

* desire for, or have received, treatment for alcohol use in the past 6 months
* non-English speaking

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Nuevo Amanecer: Promoting the Psychosocial Health of Latinas
Brief Summary: The purpose of this study is to test whether a new program Nuevo Amanecer (A New Dawn), improves the quality of life of Latinas diagnosed with breast cancer. Trained Latina counselors who have had breast cancer provide support to recently diagnosed women. The investigators call these counselors peer support counselors.


Options:
A: Inclusion Criteria:

* having received a diagnosis for a stage I-III cancer within the past 18 months;
* having a score of 7 or higher on the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D)84 or of 14 or higher on the Beck Depression Inventory-II (BDI-II);

Exclusion Criteria:

* have received bright light therapy in the past month or having previously received cognitive therapy for depression;
* having severe cognitive impairments (e.g., diagnosis of Parkinson's disease, dementia, or Mini-Mental State Examination \[MMSE\] score \< 27);
* meeting DSM-IV criteria for a major depressive episode of severe intensity, or another severe psychiatric disorder (e.g., psychotic, bipolar, or substance use disorder);
* presenting suicidal ideations with a risk of acting out, or having attempted suicide in the past five years;
* having started a new psychotropic medication or having modified the dosage or frequency of use during the past two weeks;
* currently taking a photosensitive medication (e.g., lithium, L-tryptophan);
* having evidence of an ocular pathology from an optometrist exam or a medical condition contraindicating the use of bright light therapy (e.g., severe cataracts, glaucoma, diabetes).
B: Inclusion Criteria:

* Non-metastatic breast cancer (in situ or invesive)
* End of active treatments (surgery, chemotherapy and radiotherapy)
* No recurrence nor palliative care
* Min. 18 years
* Able to speak French
* Willing to be randomized to study intervention group
* Accept to give their written informed consent

Exclusion Criteria:

* No cognitive dysfunction
* No severe or uncontrolled psychiatric illness
C: Inclusion Criteria:

* 21 years old or older
* Diagnosed with Stage 0, I, II, or III breast cancer
* Undergone lumpectomy and completed adjuvant radiation and/or chemotherapy (end of treatment to 18 months post-treatment)
* Ability to read and speak English at the 8th grade level to respond to the survey questions

Exclusion Criteria:

* Advanced stage (IV) breast cancer
* History of mastectomy
* Current psychiatric diagnosis
* Recurrent treatment for prior breast cancer
D: Inclusion Criteria:

* Self-identifies as Latina
* Diagnosed with Stage 0, I, II, or III in the prior month
* Primarily Spanish-speaking, or Spanish monolingual
* Aged 18 or older
* Diagnosed in Alameda, Contra Costa, San Mateo, San Francisco or Santa Clara counties, California.

Exclusion Criteria:

* Previous cancer diagnosis except for non-melanoma skin cancer
* Terminal illness
* Stage IV breast cancer (distant metastasis)

Answer: D